nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.11.2014 | Preclinical study

Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway

verfasst von: Jieqiong Wang, Li Zhang, Guoliang Chen, Jing Zhang, Zhenxi Li, Weiqiang Lu, Mingyao Liu, Xiufeng Pang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Signal transducer and activator of transcription 3 (STAT3) is implicated breast cancer metastasis and represents a potential target for developing new anti-tumor metastasis drugs. The purpose of this study is to investigate whether the natural agent 1′-acetoxychavicol acetate (ACA), derived from the rhizomes and seeds of Languas galanga, could suppress breast cancer metastasis by targeting STAT3 signaling pathway. ACA was examined for its effects on breast cancer migration/invasion and metastasis using Transwell assays in vitro and breast cancer skeletal metastasis mouse model in vivo (n = 10 mice per group). The inhibitory effect of ACA on cellular STAT3 signaling pathway was investigated by series of biochemistry analysis. The chavicol preferentially suppressed cancer cell migration and invasion, and this activity was superior to its cytotoxic effects. ACA suppressed both constitutive and interleukin-6-inducible STAT3 activation and diminished the accumulation of STAT3 in the nucleus and its DNA-binding activity. More importantly, ACA treatment led to significant up-regulation of Src homology region 2 domain-containing phosphatase 1 (SHP-1), and the ACA-induced depression of cancer cell migration and STAT3 signaling could be apparently reversed by blockade of SHP-1. Matrix metalloproteinase (MMP)-2 and -9, gene products of STAT3 that regulate cell invasion, were specifically suppressed by ACA. In tumor metastasis model, ACA potently inhibited the human breast cancer cell-induced osteolysis, and had little apparent in vivo toxicity at the test concentrations. ACA is a novel drug candidate for the inhibition of tumor metastasis through interference with the SHP-1/STAT3/MMPs signaling pathway.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64(1):9–29PubMedCrossRef

Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695PubMedCrossRef

Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274(2):113–126PubMedCentralPubMedCrossRef

Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904PubMedCrossRef

Wang TH, Niu GL, Kortylewski M, Burdelya L, Shain K, Zhang SM, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H (2004) Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. Nat Med 10(1):48–54PubMedCrossRef

Huang SY (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13(5):1362–1366PubMedCrossRef

Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. Curr Mol Med 9(5):626–633PubMedCrossRef

Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740–749PubMedCrossRef

Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC (2008) JAK kinases overexpression promotes in vitro cell transformation. Oncogene 27(11):1511–1519PubMedCrossRef

10.

Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T (1996) Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 16(12):6985–6992PubMedCentralPubMed

11.

Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67PubMedCentralPubMedCrossRef

12.

Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S (2004) STAT3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23(20):3550–3560PubMedCrossRef

13.

Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by STAT3-C. Proc Natl Acad Sci USA 101(29):10602–10607PubMedCentralPubMedCrossRef

14.

Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G, Bishayee A (2014) Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta 1845 2:136–154

15.

Pandey MK, Sung B, Aggarwal BB (2010) Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int J Cancer 127(2):282–292PubMedCentralPubMed

16.

Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G (2011) Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 17(6):1425–1439PubMedCrossRef

17.

Jung JE, Kim HS, Lee CS, Park DH, Kim YN, Lee MJ, Lee JW, Park JW, Kim MS, Ye SK, Chung MH (2007) Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 28(8):1780–1787PubMedCrossRef

18.

Ohnishi M, Tanaka T, Makita H, Kawamori T, Mori H, Satoh K, Hara A, Murakami A, Ohigashi H, Koshimizu K (1996) Chemopreventive effect of a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate, on rat oral carcinogenesis. Jpn J Cancer Res 87(4):349–356PubMedCrossRef

19.

Murakami A, Ohura S, Nakamura Y, Koshimizu K, Ohigashi H (1996) 1′-Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Oncology 53(5):386–391PubMedCrossRef

20.

Ohata T, Fukuda K, Murakami A, Ohigashi H, Sugimura T, Wakabayashi K (1998) Inhibition by 1′-acetoxychavicol acetate of lipopolysaccharide- and interferon-gamma-induced nitric oxide production through suppression of inducible nitric oxide synthase gene expression in RAW264 cells. Carcinogenesis 19(6):1007–1012PubMedCrossRef

21.

Tanaka T, Kawabata K, Kakumoto M, Makita H, Matsunaga K, Mori H, Satoh K, Hara A, Murakami A, Koshimizu K, Ohigashi H (1997) Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate. Jpn J Cancer Res 88(9):821–830PubMedCrossRef

22.

Kawabata K, Tanaka T, Yamamoto T, Ushida J, Hara A, Murakami A, Koshimizu K, Ohigashi H, Stoner GD, Mori H (2000) Suppression of N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis by dietary feeding of 1′-acetoxychavicol acetate. Jpn J Cancer Res 91(2):148–155PubMedCrossRef

23.

Kato R, Matsui-Yuasa I, Azuma H, Kojima-Yuasa A (2014) The synergistic effect of 1′-acetoxychavicol acetate and sodium butyrate on the death of human hepatocellular carcinoma cells. Chem Biol Interact 212C:1–10CrossRef

24.

Wang H, Shen L, Li X, Sun M (2013) MicroRNAs contribute to the anticancer effect of 1′-acetoxychavicol acetate in human head and neck squamous cell carcinoma cell line HN4. Biosci Biotechnol Biochem 77(12):2348–2355PubMedCrossRef

25.

Williams M, Tietzel I, Quick QA (2013) 1′-Acetoxychavicol acetate promotes caspase 3-activated glioblastoma cell death by overcoming enhanced cytokine expression. Oncol Lett 5(6):1968–1972PubMedCentralPubMed

26.

Moffatt J, Kennedy DO, Kojima A, Hasuma T, Yano Y, Otani S, Murakami A, Koshimizu K, Ohigashi H, Matsui-Yuasa I (2002) Involvement of protein tyrosine phosphorylation and reduction of cellular sulfhydryl groups in cell death induced by 1′-acetoxychavicol acetate in Ehrlich ascites tumor cells. Chem Biol Interact 139(2):215–230PubMedCrossRef

27.

Ito K, Nakazato T, Xian MJ, Yamada T, Hozumi N, Murakami A, Ohigashi H, Ikeda Y, Kizaki M (2005) 1′-acetoxychavicol acetate is a novel nuclear factor kappa B inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 65(10):4417–4424PubMedCrossRef

28.

Ichikawa H, Takada Y, Murakami A, Aggarwal BB (2005) Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappa B-regulated gene products. J Immunol 174(11):7383–7392PubMedCrossRef

29.

Ito K, Nakazato T, Murakami A, Ohigashi H, Ikeda Y, Kizaki M (2005) 1′-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL. Biochem Biophys Res Commun 338(4):1702–1710PubMedCrossRef

30.

Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, Zhang J, Qu W, Aggarwal BB, Liu M (2011) 1′-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis 32(6):904–912PubMedCentralPubMedCrossRef

31.

Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M (2009) Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69(14):5893–5900PubMedCentralPubMedCrossRef

32.

Li C, Yang Z, Zhai C, Qiu W, Li D, Yi Z, Wang L, Tang J, Qian M, Luo J, Liu M (2010) Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappa B signaling pathway. Mol Cancer 9:73–85PubMedCentralPubMedCrossRef

33.

Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X, Liu M (2012) Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther 11(2):277–287PubMedCrossRef

34.

Franke-Fayard B, Waters AP, Janse CJ (2006) Real-time in vivo imaging of transgenic bioluminescent blood stages of rodent malaria parasites in mice. Nat Protoc 1(1):476–485PubMedCrossRef

35.

Ihle JN (1996) STATs: signal transducers and activators of transcription. Cell 84(3):331–334PubMedCrossRef

36.

Schreiner SJ, Schiavone AP, Smithgall TE (2002) Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277(47):45680–45687PubMedCrossRef

37.

Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19(21):2548–2556PubMedCrossRef

38.

Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB, Rosen J (1995) Spacing of palindromic half sites as a determinant of selective signal transducers and activators of transcription (STAT) DNA binding and transcriptional activity. Proc Natl Acad Sci USA 92(7):3041–3045PubMedCentralPubMedCrossRef

39.

Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R (2006) Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK + anaplastic large-cell lymphoma. Blood 108(8):2796–2803PubMedCrossRef

40.

Sandur SK, Pandey MK, Sung B, Aggarwal BB (2010) 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res 8(1):107–118PubMedCentralPubMedCrossRef

41.

Wu C, Sun M, Liu L, Zhou GW (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1–12PubMedCrossRef

42.

Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L (2007) EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 282(37):26656–26664PubMedCrossRef

43.

Ostman A, Hellberg C, Bohmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6(4):307–320PubMedCrossRef

44.

Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, Aggarwal BB (2007) Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 13(10):3024–3032PubMedCrossRef

45.

Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R (2014) Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol 74(1):125–130PubMedCrossRef

46.

Gialeli C, Theocharis AD, Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278(1):16–27PubMedCrossRef

47.

Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8(3):221–233PubMedCentralPubMedCrossRef

48.

Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massague J, Kang Y (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23(16):1882–1894PubMedCentralPubMedCrossRef

49.

Orita S, Hirose M, Takahashi S, Imaida K, Ito N, Shudo K, Ohigashi H, Murakami A, Shirai T (2004) Modifying effects of 1′-acetoxychavicol acetate (ACA) and the novel synthetic retinoids Re-80, Am-580 and Am-55P in a two-stage carcinogenesis model in female rats. Toxicol Pathol 32(2):250–257PubMedCrossRef

50.

Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY (2007) NF-kappa B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13(1):62–69PubMedCrossRef

Titel: Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway
verfasst von: Jieqiong Wang
Li Zhang
Guoliang Chen
Jing Zhang
Zhenxi Li
Weiqiang Lu
Mingyao Liu
Xiufeng Pang
Publikationsdatum: 01.11.2014
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-3165-6

Springer Medizin

Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias

High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients

Racial differences in breast cancer, cardiovascular disease, and all-cause mortality among women with ductal carcinoma in situ of the breast

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie